Longitudinal assessment of Tau pathology in patients with Alzheimer's disease using [18F] THK-5117 positron emission tomography

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Ishiki, Aiko ^a   Okamura, Nobuyuki ^a,b   Furukawa, Katsutoshi ^a   Furumoto, Shozo ^a   Harada, Ryuichi ^a   Tomita, Naoki ^a   Hiraoka, Kotaro ^a   Watanuki, Shoichi ^a   Ishikawa, Yoichi ^a   Tago, Tetsuro ^a   Funaki, Yoshihito ^a   Iwata, Ren ^a   Tashiro, Manabu ^a   Yanai, Kazuhiko ^b   Kudo, Yukitsuka ^a   Arai, Hiroyuki ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPHARMACEUTICAL AGENT; TAU PROTEIN; THK 5117 F 18; UNCLASSIFIED DRUG; 6-((3-FLUORO-2-HYDROXY)PROPOXY)-2-(4-METHYLAMINOPHENYL)QUINOLINE; ANILINE DERIVATIVE; QUINOLINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG BINDING; FEMALE; FUSIFORM GYRUS; HUMAN; IMAGE ANALYSIS; INFERIOR TEMPORAL GYRUS; LONGITUDINAL STUDY; MALE; MIDDLE TEMPORAL GYRUS; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; VERY ELDERLY; CASE CONTROL STUDY; DEMOGRAPHY; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANILINE COMPOUNDS; CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; TAU PROTEINS;

EID: 84948738866     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140311     Document Type: Article

References (33)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991 Sep; 82(4):239-259. PMID: 1759558
2. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012 Jan; 8(1):1-13. doi: 10.1016/j.jalz.2011.10.007 PMID: 22265587
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002 Jul. 19; 297(5580):353-356. PMID: 12130773
4. Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides. 2015 Aug; 52:1-18. doi: 10.1016/j.npep. 2015.06.008 PMID: 26149638
5. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. Nature Publishing Group; 2010 May; 9(5):387-398.
6. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004 Mar; 55(3):306-319. PMID: 14991808
7. Rowe CC, Villemagne VL. Amyloid imaging with PET in early Alzheimer disease diagnosis. Med Clin North Am. 2013 May; 97(3):377-398. doi: 10.1016/j.mcna.2012.12.017 PMID: 23642577
8. Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol. 1995 Oct; 38(4):649-652. PMID: 7574462
9. Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol. 2001 Aug; 50(2):150-156. PMID: 11506396
10. Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, et al. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging. 2013 Jan; 40(1):125-132. doi: 10.1007/s00259-012-2261-2 PMID: 23100049
11. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013 Sep. 18; 79(6):1094-1108. doi: 10.1016/j.neuron. 2013.07.037 PMID: 24050400
12. Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013 Aug. 1; 54(8):1420-1427. doi: 10.2967/jnumed.112.117341 PMID: 23857514
13. Xia C-F, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18) F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013 Nov; 9(6):666-676. doi: 10.1016/j.jalz.2012.11.008 PMID: 23411393
14. Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014 Jan; 38(1):171-184. doi: 10. 3233/JAD-130098 PMID: 23948934
15. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. [(18) F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2015 Jun; 42(7):1052-1061. doi: 10.1007/s00259-015-3035-4 PMID: 25792456
16. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su M-Y, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013 Jan; 34(2):457-468. doi: 10. 3233/JAD-122059 PMID: 23234879
17. Arriagada P V, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992 Mar; 42(3 Pt 1):631-639. PMID: 1549228
18. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012 May; 71(5):362-381. PMID: 22487856
19. Hyman BT, Marzloff K, Arriagada P V. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol. 1993 Nov; 52(6):594-600. PMID: 8229078
20. Nordberg A, Rinne JO, Kadir A, Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol. Nature Publishing Group; 2010 Feb; 6(2):78-87.
21. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology. 1999 Apr. 12; 52(6):1158-1165. PMID: 10214737
22. Jobst KA, Smith AD, Szatmari M, Esiri MM, Jaskowski A, Hindley N, et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet. 1994 Apr; 343(8901):829-830. PMID: 7908080
23. Jack CR, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology. 1998 Oct; 51(4):993-999. PMID: 9781519
24. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984 Sep. 14; 225(4667):1168-1170. PMID: 6474172
25. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006 Nov. 1; 129(Pt 11):2856-2866. PMID: 16854944
26. Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010 Nov. 1; 133(11):3336-3348. doi: 10.1093/brain/awq277 PMID: 20935035
27. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol. 2011 Jan; 69(1):181-192. doi: 10. 1002/ana.22248 PMID: 21280088
28. Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and earlystage Alzheimer's disease. J Mol Neurosci. 2001 Oct; 17(2):101-118. PMID: 11816784
29. Price JL, Morris JC. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol. 1999 Mar; 45(3):358-368. PMID: 10072051
30. Kuzuhara S, Ihara Y, Toyokura Y, Shimada H. [A semiquantitative study on Alzheimer neurofibrillary tangles demonstrated immunohistochemically with anti-tau antibodies, in the brains of non-demented and demented old people]. No To Shinkei. 1989 May; 41(5):465-470. PMID: 2508732
31. Sun Y, Yang F-C, Lin C-P, Han Y. Biochemical and Neuroimaging Studies in Subjective Cognitive Decline: Progress and Perspectives. CNS Neurosci Ther. 2015 Apr. 13. doi: 10.1111/cns.12395
32. Mendonca MD, Alves L, Bugalho P. From Subjective Cognitive Complaints to Dementia: Who Is at Risk?: A Systematic Review. Am J Alzheimers Dis Other Demen. 2015 Jul. 3. pii: 1533317515592331.
33. Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging. 2009 Apr; 13(4):367-369. PMID: 19300883